

# Georg Hempel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5167498/publications.pdf>

Version: 2024-02-01

123  
papers

3,695  
citations

147801

31  
h-index

155660

55  
g-index

127  
all docs

127  
docs citations

127  
times ranked

4988  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated <i>E. coli</i> asparaginase in children with acute lymphocytic leukemia. <i>Haematologica</i> , 2022, 107, 49-57.	3.5	26
2	Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients. <i>European Journal of Cancer</i> , 2022, 164, 127-136.	2.8	19
3	Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veneno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 196-202.	1.2	12
4	Hypericum perforatum and Its Ingredients Hypericin and Pseudohypericin Demonstrate an Antiviral Activity against SARS-CoV-2. <i>Pharmaceuticals</i> , 2022, 15, 530.	3.8	22
5	Pharmacokinetic modelling of caspofungin to develop an extended dosing regimen in paediatric patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2209-2216.	3.0	1
6	Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400Âmg. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 125-136.	2.3	2
7	Population pharmacokinetics of vancomycin in patients with external ventricular drain-associated ventriculitis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2502-2510.	2.4	12
8	Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	6
9	Population pharmacokinetic evaluation of cefuroxime in perioperative antibiotic prophylaxis during and after cardiopulmonary bypass. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1486-1498.	2.4	1
10	Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling. <i>Clinical Pharmacokinetics</i> , 2021, 60, 261-270.	3.5	12
11	In vitro screening of plant extracts traditionally used as cancer remedies in Ghana â€“ 15-Hydroxyangustilobine A as the active principle in <i>Alstonia boonei</i> leaves. <i>Journal of Ethnopharmacology</i> , 2021, 265, 113359.	4.1	13
12	Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 289-300.	1.6	6
13	Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1569-1582.	3.5	11
14	Identification of factors for a successful implementation of medication reviews in community pharmacies: Using Positive Deviance in pharmaceutical care. <i>International Journal of Clinical Pharmacy</i> , 2021, , 1.	2.1	6
15	Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. <i>Cancers</i> , 2021, 13, 6281.	3.7	8
16	Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes. <i>Clinical Pharmacokinetics</i> , 2020, 59, 51-65.	3.5	15
17	Validation and clinical application of a volumetric absorptive microsampling method for 14 psychiatric drugs. <i>Bioanalysis</i> , 2020, 12, 1129-1147.	1.5	11
18	Improving medication appropriateness in nursing homes via structured interprofessional medication-review supported by health information technology: a non-randomized controlled study. <i>BMC Geriatrics</i> , 2020, 20, 506.	2.7	4

#	ARTICLE	IF	CITATIONS
19	Bioanalysis of doxorubicin aglycone metabolites in human plasma samplesâ€“implications for doxorubicin drug monitoring. <i>Scientific Reports</i> , 2020, 10, 18562.	3.3	9
20	Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature. <i>Planta Medica</i> , 2020, 86, 659-664.	1.3	72
21	Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach. <i>Pharmaceutical Research</i> , 2020, 37, 110.	3.5	5
22	Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure. <i>BMC Pharmacology &amp; Toxicology</i> , 2020, 21, 37.	2.4	7
23	Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the â€œEuropean Paediatric Oncology Off-patents Medicines Consortiumâ€•(EPOC) Trial. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 413-422.	1.6	7
24	The challenge to define a relevant change in medication appropriateness index score in older adults â€“ An approach. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 398-399.	2.4	2
25	The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing Sarcoma. <i>Cancers</i> , 2020, 12, 904.	3.7	2
26	How physiologically-based pharmacokinetic models should be improved for drug development. <i>Future Medicinal Chemistry</i> , 2020, 12, 1107-1109.	2.3	1
27	Continuous infusion of physostigmine in patients with perioperative septic shock: A pharmacokinetic/pharmacodynamic study with population pharmacokinetic modeling. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109318.	5.6	3
28	Physiologically based pharmacokinetic evaluation of cefuroxime in perioperative antibiotic prophylaxis. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2864-2877.	2.4	8
29	Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemiaâ€“a report from the UKALL 2011 trial. <i>European Journal of Cancer</i> , 2019, 120, 75-85.	2.8	18
30	Extended Dosing Regimens for Fungal Prophylaxis. <i>Clinical Microbiology Reviews</i> , 2019, 32, .	13.6	17
31	Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure. <i>BMC Pharmacology &amp; Toxicology</i> , 2019, 20, 16.	2.4	12
32	Pharmacokinetics of Micafungin in Critically Ill Patients. <i>Scientific Reports</i> , 2019, 9, 17741.	3.3	8
33	Pharmacotherapy in Children and Adolescents: Oncology. <i>Handbook of Experimental Pharmacology</i> , 2019, 261, 415-440.	1.8	0
34	Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 427-441.	2.3	15
35	An ethnopharmacological survey of medicinal plants traditionally used for cancer treatment in the Ashanti region, Ghana. <i>Journal of Ethnopharmacology</i> , 2018, 212, 137-152.	4.1	50
36	Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	25

#	ARTICLE	IF	CITATIONS
37	A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways. <i>Clinical Pharmacokinetics</i> , 2018, 57, 749-768.	3.5	60
38	Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 305-314.	2.3	18
39	Investigation of the age dependency of vancomycin clearance by population pharmacokinetic modeling. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2018, 56, 56-63.	0.6	12
40	Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1525-1541.	3.5	63
41	Gestation-Specific Changes in the Anatomy and Physiology of Healthy Pregnant Women: An Extended Repository of Model Parameters for Physiologically Based Pharmacokinetic Modeling in Pregnancy. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1303-1330.	3.5	81
42	Validation of a dried blood spot method for therapeutic drug monitoring of citalopram, mirtazapine and risperidone and its active metabolite 9-hydroxyrisperidone using HPLC-MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 140, 347-354.	2.8	28
43	Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 955-963.	1.6	16
44	Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients. <i>Clinical Pharmacokinetics</i> , 2017, 56, 759-779.	3.5	23
45	Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 333-342.	1.9	33
46	Effect of training and structured medication review on medication appropriateness in nursing home residents and on cooperation between health care professionals: the InTherAKT study protocol. <i>BMC Geriatrics</i> , 2017, 17, 24.	2.7	14
47	Towards a Model-Based Dose Recommendation for Doxorubicin in Children. <i>Clinical Pharmacokinetics</i> , 2017, 56, 215-223.	3.5	5
48	Addressing Adherence Using Genotype-Specific PBPK Modeling—Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels. <i>Frontiers in Pharmacology</i> , 2017, 8, 67.	3.5	3
49	Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 603-610.	0.8	25
50	The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 661-671.	2.3	297
51	Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a “European Pediatric Oncology Off-patents Medicines Consortium” trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1175-1184.	2.3	25
52	Impact of medication therapy management in patients with Parkinson’s disease. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 54-60.	2.1	13
53	Development and validation of an HPLC method for the determination of vancomycin in human plasma and its comparison with an immunoassay (PETINIA). <i>SpringerPlus</i> , 2016, 5, 124.	1.2	40
54	EUROPEAN PAEDIATRIC ONCOLOGY OFF-PATENT MEDICINES CONSORTIUM (EPOC): A PHARMACOKINETIC STUDY OF DOXORUBICIN IN CHILDREN WITH CANCER. <i>Archives of Disease in Childhood</i> , 2016, 101, e1.6-e1.	1.9	0

#	ARTICLE	IF	CITATIONS
55	Asymmetrical flow field-flow fractionation for the analysis of PEG-asparaginase. <i>Talanta</i> , 2016, 146, 335-339.	5.5	5
56	Quantitative analysis of DNA methylation in the promoter region of the methylguanineâ€ <sup>6</sup> â€DNAâ€methyltransferase gene by COBRA and subsequent native capillary gel electrophoresis. <i>Electrophoresis</i> , 2015, 36, 2939-2950.	2.4	3
57	Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1139-1149.	3.5	23
58	Clinical Pharmacology of Itraconazole in Children and Adolescents. <i>Current Fungal Infection Reports</i> , 2015, 9, 65-73.	2.6	2
59	Discrepancies on Medication Plans detected in <sc>G</sc>erman Community Pharmacies. <i>Journal of Evaluation in Clinical Practice</i> , 2015, 21, 886-892.	1.8	23
60	Physiology-Based Pharmacokinetics of Caspofungin for Adults and Paediatrics. <i>Pharmaceutical Research</i> , 2015, 32, 2029-2037.	3.5	13
61	Predictive Performance of a Physiologically Based Pharmacokinetic Model of Busulfan in Children. <i>Pediatric Hematology and Oncology</i> , 2014, 31, 731-742.	0.8	21
62	Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients. <i>Pediatric Blood and Cancer</i> , 2014, 61, 306-311.	1.5	4
63	Physiology-Based Pharmacokinetic Modelingâ€”Promise for Pediatric Drug Development?. <i>Current Fungal Infection Reports</i> , 2014, 8, 67-71.	2.6	0
64	Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEMÂ® model to optimize dosing. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 839-847.	1.9	16
65	Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling. <i>Molecular Cancer</i> , 2014, 13, 174.	19.2	45
66	Comparative pharmacokinetic/pharmacodynamic characterisation of a new pegylated recombinant E. coli l-asparaginase preparation (MC0609) in Beagle dog. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 367-378.	2.3	6
67	Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling. <i>SpringerPlus</i> , 2014, 3, 285.	1.2	12
68	Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1149-1155.	2.3	14
69	Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 991-1000.	2.3	14
70	Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3Âyears. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 749-763.	2.3	35
71	Population Pharmacokinetics of Escalating Doses of Caspofungin in a Phase II Study of Patients with Invasive Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1664-1671.	3.2	44
72	Population Pharmacokinetics of Native <i>Escherichia Coli</i>Asparaginase. <i>Pediatric Hematology and Oncology</i> , 2012, 29, 154-165.	0.8	8

#	ARTICLE	IF	CITATIONS
73	Plasma Concentrations of Posaconazole Administered via Nasogastric Tube in Patients in a Surgical Intensive Care Unit. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4468-4470.	3.2	20
74	Population Pharmacokinetics of Liposomal Amphotericin B and Caspofungin in Allogeneic Hematopoietic Stem Cell Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 536-543.	3.2	46
75	Minimization of the Preanalytical Error in Pharmacokinetic Analyses and Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 460-466.	2.0	9
76	Population Pharmacokinetics of Busulfan in Childrenâ€“Response. <i>Clinical Cancer Research</i> , 2012, 18, 2717-2718.	7.0	1
77	Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance. <i>Frontiers in Pharmacology</i> , 2012, 3, 92.	3.5	30
78	Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 923-935.	1.9	7
79	Genome-wide DNA methylation level analysis by micellar electrokinetic chromatography and laser-induced fluorescence detection after treatment of cell lines with azacytidine and antifolates. <i>Analytical Biochemistry</i> , 2012, 421, 439-445.	2.4	7
80	Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 397-405.	2.3	31
81	The management of hypertensive emergencies in children after stem cell transplantation. <i>International Journal of Clinical Pharmacy</i> , 2011, 33, 165-176.	2.1	7
82	Minimization of the Preanalytical Error in Plasma Samples for Pharmacokinetic Analyses and Therapeutic Drug Monitoring - Using Doxorubicin as an Example. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 766-771.	2.0	16
83	Therapeutic Drug Monitoring of Busulfan. <i>Clinical Chemistry</i> , 2011, 57, 643-644.	3.2	1
84	Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children. <i>Clinical Cancer Research</i> , 2011, 17, 6867-6877.	7.0	54
85	Therapeutic Drug Monitoring of Methotrexate in Cerebrospinal Fluid After Systemic High-Dose Infusion in Children: Can the Burden of Intrathecal Methotrexate be Reduced?. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 467-475.	2.0	18
86	Pharmacokinetics of linezolid in septic patients with and without extended dialysis. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 291-298.	1.9	68
87	Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. <i>Pediatric Blood and Cancer</i> , 2010, 54, 355-360.	1.5	20
88	Therapeutic drug monitoring of asparaginase in the ALLâ€“BFM 2000 protocol between 2000 and 2007. <i>Pediatric Blood and Cancer</i> , 2010, 54, 952-958.	1.5	44
89	A population pharmacokinetic model for pegylatedâ€“asparaginase in children. <i>British Journal of Haematology</i> , 2010, 148, 119-125.	2.5	32
90	Accurate quantification of DNA methylation of <i>DRD4</i> applying capillary gel electrophoresis with LIF detection. <i>Electrophoresis</i> , 2009, 30, 1412-1417.	2.4	8

#	ARTICLE	IF	CITATIONS
91	Determination of DNA methylation by COBRA: A comparative study of CGE with LIF detection and conventional gel electrophoresis. <i>Electrophoresis</i> , 2009, 30, 3063-3070.	2.4	13
92	Cytotoxicity of Dimethylacetamide and Pharmacokinetics in Children Receiving Intravenous Busulfan. <i>Journal of Clinical Oncology</i> , 2007, 25, 1772-1778.	1.6	38
93	Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group. <i>Clinical Cancer Research</i> , 2007, 13, 6410-6418.	7.0	101
94	Flat-Fixed Dosing Versus Body Surface Area-Based Dosing of Anticancer Drugs: There Is a Difference. <i>Oncologist</i> , 2007, 12, 924-926.	3.7	13
95	Population Pharmacokinetics of the BEACOPP Polychemotherapy Regimen in Hodgkin's Lymphoma and its Effect on Myelotoxicity. <i>Clinical Pharmacokinetics</i> , 2007, 46, 319-333.	3.5	18
96	Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2007, 46, 1051-1068.	3.5	42
97	Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. <i>Cancer</i> , 2007, 110, 103-111.	4.1	599
98	Comment on "Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation" by F.K. Glowka et al. [ <i>J. Chromatogr. B</i> 850 (2007) 569-574]. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 853, 369-370.	2.3	0
99	Monitoring of N,N-dimethylacetamide in children during i.v.-busulfan therapy by liquid chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 838, 129-134.	2.3	24
100	Quantification of ganciclovir in human plasma using capillary electrophoresis. <i>Electrophoresis</i> , 2006, 27, 2439-2443.	2.4	9
101	Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation. <i>Anti-Cancer Drugs</i> , 2005, 16, 337-344.	1.4	23
102	Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery. <i>European Journal of Clinical Pharmacology</i> , 2005, 60, 883-888.	1.9	24
103	Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 55, 347-353.	2.3	24
104	Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 322-327.	2.3	3
105	Population Pharmacokinetics of Amphotericin B Lipid Complex in Neonates. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 5092-5098.	3.2	107
106	Population pharmacokinetics of oral busulfan in children. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 209-216.	2.3	43
107	Population pharmacokinetics of liposomal daunorubicin in children. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 370-377.	2.4	29
108	Biomedical Applications of Capillary Electrophoresis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 720-3.	2.3	23

#	ARTICLE	IF	CITATIONS
109	Population pharmacokinetics of low-dose paclitaxel in patients with brain tumors. <i>Anti-Cancer Drugs</i> , 2003, 14, 417-422.	1.4	10
110	Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2002, 366, 218-225.	3.0	7
111	Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 49, 133-141.	2.3	45
112	Determination of free and liposome-associated daunorubicin and daunorubicinol in plasma by capillary electrophoresis. <i>Journal of Chromatography A</i> , 2002, 979, 379-388.	3.7	41
113	Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of l-asparaginase in human serum. <i>Analytical Biochemistry</i> , 2002, 309, 117-126.	2.4	76
114	Quantification of daunorubicin and daunorubicinol in plasma by capillary electrophoresis. <i>Biomedical Applications</i> , 2001, 758, 221-228.	1.7	15
115	Strategies to improve the sensitivity in capillary electrophoresis for the analysis of drugs in biological fluids. <i>Electrophoresis</i> , 2000, 21, 691-698.	2.4	148
116	Determination of purines including 2,8-dihydroxyadenine in urine using capillary electrophoresis. <i>Journal of Chromatography A</i> , 2000, 894, 157-164.	3.7	36
117	Strategies to improve the sensitivity in capillary electrophoresis for the analysis of drugs in biological fluids. <i>Electrophoresis</i> , 2000, 21, 691-698.	2.4	1
118	Determination of (E)-5-(2-bromovinyl)-2'-deoxyuridine in plasma and urine by capillary electrophoresis. <i>Biomedical Applications</i> , 1999, 726, 261-268.	1.7	21
119	Therapeutic drug monitoring of doxorubicin in paediatric oncology using capillary electrophoresis. <i>Electrophoresis</i> , 1998, 19, 2939-2943.	2.4	51
120	Capillary electrophoretic drug monitoring of methotrexate and leucovorin and their metabolites. <i>Biomedical Applications</i> , 1998, 718, 177-185.	1.7	36
121	Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis. <i>Biomedical Applications</i> , 1997, 698, 287-292.	1.7	37
122	Determination of paclitaxel in biological fluids by micellar electrokinetic chromatography. <i>Journal of Chromatography A</i> , 1996, 745, 173-179.	3.7	70
123	Preparative and analytical separation of the zopiclone enantiomers and determination of their affinity to the benzodiazepine receptor binding site. <i>Chirality</i> , 1993, 5, 419-421.	2.6	48